샘플 요청 목록

 카트 문의
시장보고서
상품코드
1986393

신장 기능 검사 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 용도별, 지역별 및 부문별 예측(2026-2033년)

Kidney Function Tests Market Size, Share & Trends Analysis Report By Product (Clearance Tests, Urine Tests, Blood Tests, Dilution And Concentration Tests), By End Use (Hospitals, Diagnostic Laboratories), By Region, And Segment Forecasts, 2026 - 2033
발행일: | 리서치사: 구분자 Grand View Research | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




가격
Unprintable PDF & Excel (Single User License) help
보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.
US $ 5,950 금액 안내 화살표 ￦ 8,854,000
Printable PDF & Excel (5-User License) help
보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.
US $ 6,950 금액 안내 화살표 ￦ 10,342,000
Printable PDF & Excel (Enterprise License) help
PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.
US $ 8,950 금액 안내 화살표 ￦ 13,319,000
카드담기
※ 부가세 별도
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

신장 기능 검사 시장 요약

세계의 신장 기능 검사 시장 규모는 2025년에 11억 2,000만 달러로 평가되며, 2033년까지 17억 7,000만 달러에 달할 것으로 예측되고 있으며, 2026-2033년에 CAGR 5.87%로 성장할 것으로 전망되고 있습니다.

시장 성장을 이끄는 요인으로는 업계 관계자들의 투자 증가, 연구개발 활동 증가, 높은 신장 질환 유병률, 정부의 노력, 기술 발전 등을 꼽을 수 있습니다.

예를 들어 2024년 2월 Simple HealthKit은 당뇨병을 위한 새로운 신장 기능 평가 검사를 출시했습니다. 이 검사는 의료기관 및 재택 환경에서 사용할 수 있습니다. 이러한 발전은 신장 기능 검사 산업의 성장을 촉진할 것으로 보입니다.

COVID-19 팬데믹 기간 중 신장 손상 발생률이 눈에 띄게 증가했습니다. 연구에 따르면 기존 신장 질환을 앓고 있는 사람들이 COVID-19에 감염되면 심각한 합병증 위험이 높고 예후가 좋지 않은 것으로 나타났습니다. COVID-19의 장기적 영향에 대한 지속적인 연구에서도 신장 건강에 대한 잠재적인 지속적 영향이 드러나고 있습니다. 하지만, 코로나 사태로 인해 신장병 환자들에 대한 의료서비스는 혼란에 빠졌다. 록다운과 사회적 거리두기 의무화로 인해 긴급을 요하지 않는 의료서비스가 일시적으로 중단되었기 때문입니다. 그 결과, 전염병이 한창인 시기에 정기적인 진료와 진단 검사가 중단되어 신장 질환의 진단이 늦어지는 사태가 발생했습니다.

급성 신장 질환(AKI)의 유병률 증가와 만성 신장 질환(CKD)으로 진행되는 경향은 예측 기간 중 신장 기능 검사 시장을 촉진할 것으로 예상됩니다. CKD는 최소 3개월 이상 지속되는 신장의 구조적, 기능적 이상을 말합니다. 생활습관병과 신장질환은 CKD의 주요 원인이며, CKD는 여전히 전 세계에서 이환율과 사망률의 주요 원인이 되고 있는 글로벌 건강 문제입니다. 세계보건기구(WHO)에 따르면 지난 10년간 신장 질환은 전 세계 사망 원인 중 10위권 안에 들 정도로 증가했습니다. 또한 미국 신장 재단의 보고에 따르면 미국에서는 약 3,700만 명, 즉 성인 7명 중 1명 이상이 신장 질환을 앓고 있는 것으로 나타났습니다.

자주 묻는 질문

  • 신장 기능 검사 시장 규모는 어떻게 예측되나요?
  • 신장 기능 검사 시장의 성장 요인은 무엇인가요?
  • COVID-19 팬데믹이 신장 기능 검사에 미친 영향은 무엇인가요?
  • 급성 신장 질환(AKI)과 만성 신장 질환(CKD)의 유병률은 어떻게 되나요?
  • 신장 질환의 유병률은 어떻게 되나요?

목차

제1장 조사 방법과 범위

제2장 개요

제3장 신장 기능 검사 시장 변수, 동향 및 범위

제4장 신장 기능 검사 시장 : 제품별 추정·동향 분석

제5장 신장 기능 검사 시장 : 최종 용도별 추정·동향 분석

제6장 신장 기능 검사 시장 : 지역별 추정·동향 분석

제7장 경쟁 구도

KSA 26.04.28

Kidney Function Tests Market Summary

The global kidney function tests market size was valued at USD 1.12 billion in 2025 and is projected to reach USD 1.77 billion by 2033, growing at a CAGR of 5.87% from 2026 to 2033. Several factors are anticipated to drive market growth, including increased investments by industry players, growing research and development efforts, a high prevalence of renal diseases, government initiatives, and advancements in technology.

For instance, in February 2024, Simple HealthKit launched a new renal evaluation test for diabetes. The test is available for clinics and at home settings. Such developments are likely to propel the growth of kidney function tests industry.

During the COVID-19 pandemic, the incidence of renal injury increased significantly. Research highlighted that the individuals with pre-existing renal conditions faced a higher risk of severe complications and poorer outcomes upon contracting COVID-19. Ongoing studies on the long-term effects of COVID-19 have also revealed its potential lasting impact on renal health. However, the pandemic disrupted healthcare services for renal disease patients, as lockdowns and social distancing mandates led to temporary closures of non-emergency medical services. This resulted in delays in diagnosing renal diseases due to the suspension of routine visits and diagnostic tests during peak pandemic phases.

The rising prevalence of acute kidney injury (AKI) and its progression to CKD is expected to propel the kidney function tests industry in the forecast period. CKD refers to persistent structural and functional abnormalities in the kidneys lasting at least three months. Conditions such as lifestyle-related diseases and kidney injuries are major contributors to CKD, which remains a global health burden and a leading cause of morbidity and mortality worldwide. According to the World Health Organization (WHO), renal disease has risen to become one of the top 10 leading causes of death globally over the past decade. Additionally, the National Kidney Foundation reports that approximately 37 million people in the U.S., or over one in seven adults, are affected by some form of renal disease.

Global Kidney Function Tests Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the global kidney function tests on the basis of product, end use, and region.

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Clearance Tests
  • Urine Tests
  • Blood Tests
  • Dilution And Concentration Tests
  • Other Tests
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Diagnostic Laboratories
  • Research Laboratories and Institutes
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. End use
    • 1.2.3. Application
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. End use outlook
    • 2.2.3. Application outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Kidney Function Tests Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Introduction Of Innovative Kidney Function Tests
      • 3.2.1.2. Increasing Investments In R&D
      • 3.2.1.3. Increasing Prevalence of Acute Kidney Injury And Associated Chronic Kidney Disease
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Low Awareness Regarding Kidney Diseases
  • 3.3. Kidney Function Tests Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Kidney Function Tests Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2025 & 2033
  • 4.2. Segment Dashboard
  • 4.3. Global Kidney Function Tests Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 4.4.1. Clearance Tests
      • 4.4.1.1. Market estimates and forecasts 2021 to 2033 (USD million)
    • 4.4.2. Blood Tests
      • 4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.3. Urine Tests
      • 4.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.4. Dilution & Concentration Tests
      • 4.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.5. Other Tests
      • 4.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Kidney Function Tests Market: End Use Estimates & Trend Analysis

  • 5.1. End Use Market Share, 2025 & 2033
  • 5.2. Segment Dashboard
  • 5.3. Global Kidney Function Tests Market by End Use Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 5.4.1. Hospitals
      • 5.4.1.1. Market estimates and forecasts 2021 to 2033 (USD million)
    • 5.4.2. Diagnostic Laboratories
      • 5.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.3. Research Laboratories And Institutes
      • 5.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.4. Others
      • 5.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Kidney Function Tests Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2025 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.3. Mexico
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6. Europe
    • 6.6.1. UK
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.2. Germany
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.3. France
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.4. Italy
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/ reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.5. Spain
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/ reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.6. Norway
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/ reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.7. Sweden
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/ reimbursement structure
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.8. Denmark
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/ reimbursement structure
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/ reimbursement structure
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/ reimbursement structure
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/ reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.8.2. Argentina
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/ reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Regulatory framework/ reimbursement structure
      • 6.9.1.3. Competitive scenario
      • 6.9.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/ reimbursement structure
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/ reimbursement structure
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/ reimbursement structure
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. Key company market share analysis, 2025
    • 7.3.2. Abbott
      • 7.3.2.1. Company overview
      • 7.3.2.2. Financial performance
      • 7.3.2.3. Product benchmarking
      • 7.3.2.4. Strategic initiatives
    • 7.3.3. Danaher
      • 7.3.3.1. Company overview
      • 7.3.3.2. Financial performance
      • 7.3.3.3. Product benchmarking
      • 7.3.3.4. Strategic initiatives
    • 7.3.4. F. Hoffmann-La Roche Ltd
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Sysmex Corporation
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Siemens Healthineers
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Randox Laboratories Ltd
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Quest Diagnostics
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Acon Laboratories, Inc
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Nova Biomedical Corporation
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. Laboratory Corporation Of America Holdings
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제